Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (125)	1/9/2007 4:34:03 PM
From: tuck	Read Replies (1) \| Respond to of 250

It seems a lot of folks are lining up to take a swing at Cabilly 2, including the Feds and the patent office itself! investorshub.com All things considered, I dared to buy a few puts this afternoon. I suspect that the climb up the wall of worry is about to end, unless DNA knocks the cover off of estimates/guidance. Something that that the CEO's recent comments would seem to discount. Cheers, Tuck

To: tuck who wrote (125)	6/11/2008 5:16:23 PM
From: tuck	Read Replies (1) \| Respond to of 250

>>Genentech Settles Dispute Related to Cabilly Patent Wednesday June 11, 4:10 pm ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc. (NYSE: DNA - News) announced today that it has settled its patent litigation with MedImmune, Inc. involving the Cabilly patent (U.S. Patent No. 6,331,415), which is co-owned by Genentech and City of Hope and relates in part to methods of producing antibodies. Under the terms of the settlement agreement, the litigation, which was pending before the U.S. District Court for the Central District of California, has now been fully resolved and dismissed. The settlement resolves disputed issues with respect to MedImmune’s marketed product Synagis® (palivizumab) as well as a related product (motavizumab) for which MedImmune is seeking regulatory approval. The settlement also permits MedImmune to obtain licenses for certain additional pipeline products under the Cabilly patent family. MedImmune filed its original complaint in April 2003. Following a U.S. Supreme Court decision in January 2007, the case was returned to the lower courts for further proceedings. Financial terms of the settlement were not disclosed. In connection with this settlement and the associated licenses, Genentech is not updating its forecasted royalty revenue.<< snip Cheers, Tuck